CLINICAL_TRIALS
withdrawal
· 2025-07-23
Clinical Trial Update: Safety, Tolerability and Efficacy of JCXH-211 in Patients With Recurrent or Progressive High-Grade Glioma [Phase 1]
Summary
The Phase 1 trial of JCXH-211 in patients with recurrent or progressive high-grade glioma has been withdrawn.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Duke University | Conditions: Recurrent or Progressive High-grade Glioma | Phase 1 | Status: WITHDRAWN